| 今开：0.0 | 昨收：11.82 |
| 最高：0.0 | 最低：0.0 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：4.98665659E8 |
KalVista(KALV)01-13 05:35
$KalVista制药(KALV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-24-001515 Size: 5 KB 网页链接查看全文
KalVista(KALV)02-06 07:05
$KalVista制药(KALV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-002625 Size: 7 KB 网页链接查看全文
KalVista(KALV)02-09 22:25
$KalVista制药(KALV)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000315066-24-001216 Act: 34 Size: 8 KB 网页链接查看全文
KalVista(KALV)03-12 04:35
$KalVista制药(KALV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-029314 Act: 34 Size: 4 MB 网页链接查看全文
KalVista(KALV)04-02 04:46
$KalVista(KALV)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-083385 Act: 34 Size: 67 KB 网页链接查看全文
KalVista(KALV)03-09 05:55
$KalVista制药(KALV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-007363 Size: 6 KB 网页链接查看全文
KalVista(KALV)02-13 22:25
$KalVista制药(KALV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-003485 Size: 8 KB 网页链接查看全文
KalVista(KALV)2023-08-22 08:15
$KalVista制药(KALV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-046822 Size: 15 KB 网页链接查看全文
KalVista(KALV)2023-12-29 05:35
$KalVista制药(KALV)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-23-059906 Size: 15 KB 网页链接查看全文
产业链观察2022-10-04 18:37
药闻▶$KalVista制药(KALV)$ 宣布终止KVD824预防治疗遗传性血管性水肿的2期KOMPLETE试验。
该决定是基于观察到试验中所有治疗组的多名患者的肝酶（ALT/AST）升高。查看全文
chuminhua2021-09-15 21:07
9月14日，KalVista早间宣布，FDA在审查了该公司对与某些临床前试验有关的更多信息和分析要求的答复后，解除了对KalVista公司KVD824项目的临床搁置。 这一消息使这家跨大西洋的生物技术公司的股票KALV在盘前交易中上涨6.25%。
KalVista公司在英国进行了KVD824的I期试验，因此II期试验KOMPLETE将...查看全文
蹊之美股生物医药2021-04-22 21:15
作者：Dr. Sun
微信公众号：蹊之美股生物医药 / CaesarBiotech
标的公司：KALV
1、KVD824 2期临床试验被FDA暂停
2、KVD900 3期临床研究计划不受影响
KalVista Pharmaceuticals，Inc.（KALV）今天宣布，美国食品药品监督管理局（FDA）通知公司，该公司已将KVD824，2期临床...查看全文
牛唐2021-04-21 12:11
医药板块观察（2021.04.20）
本期内容提示：
1、机构重仓的CNS药企$Prothena Corporation plc(PRTA)$ 如何配置？
2、$KalVista制药(KALV) FDA暂停了公司研发管线，是否迎来配置机会？
3、$居里(CRIS)三天跌去20%，机构看好的抱团股要崩了吗？
$特...查看全文
chuminhua2021-04-21 11:46
4月20日，KalVista制药公司的遗传性血管性水肿（HAE）希望之星KVD824的中期研究已被美国FDA暂停临床试验，因为它要求更多的临床前数据和对其方案进行修改。
这家英国-美国生物技术公司在一份声明中说。"2021年早些时候提交了一份新药研究申请，用于评估KVD824作为预防HAE发作[一种严重的皮...查看全文
chuminhua2021-02-10 15:01
2/9，KalVista Pharmaceuticals股价大涨高达189%，此前该公司报告称，在一项针对遗传性血管性水肿(HAE)发作患者的II期研究中，实验性药物KVD900显著降低了对救援药物的需求。首席执行官Andrew Crockett表示，顶线数据显示，这种血浆kallikrein抑制剂 "是第一个取得与目前注射疗法相当的临床疗...查看全文
chuminhua2020-02-12 16:32
2/11，KalVista Pharmaceuticals$KalVista制药(KALV)$ 表示MSD将不再继续推进与该公司合作的玻璃体内糖尿病性黄斑水肿（DME）候选药物KVD001的开发。该药物为血浆激肽释放酶抑制剂。KalVista表示将继续开发该药物。2017年MSD支付3700万美元前期款以及后续7.6亿美元里程金获得该药物授权。KalVista...查看全文
群氓鄙陋2018-08-22 03:48
$KalVista Pharmaceuticals, Inc.(KALV)$ 这是涨不停的节奏哦//@群氓毕现:回复@淘沙见金:请问 $KalVista Pharmaceuticals, Inc.(KALV)$ 不知是否有做空的机会？查看全文
$KalVista Pharmaceuticals, Inc.(KALV)$ 8-K - Current report Filed: 2018-08-01 AccNo: 0001564590-18-018511 Size: 211 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2018-08-01 AccNo: 0001564590-18-018503 Size: 686 KB 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ 8-K - Current report Filed: 2018-07-31 AccNo: 0001564590-18-017996 Size: 8 MBItem 1.02: Termination of a Material Definitive AgreementItem 2.02: Results of Operations and Financial ConditionItem 7.01: Regulation FD DisclosureItem 9.01: F...
$KalVista Pharmaceuticals, Inc.(KALV)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-07-30 AccNo: 0001564590-18-017916 Size: 169 KB 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-07-30 AccNo: 0001564590-18-017915 Size: 7 MB 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-07-30 AccNo: 0001564590-18-017916 Size: 169 KB 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-07-30 AccNo: 0001564590-18-017915 Size: 7 MB 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ 8-K - Current report Filed: 2018-06-29 AccNo: 0001564590-18-016455 Size: 1 MBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem...
$KalVista Pharmaceuticals, Inc.(KALV)$ 8-K - Current report Filed: 2018-05-02 AccNo: 0001564590-18-010068 Size: 985 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$KalVista Pharmaceuticals, Inc.(KALV)$ 8-K - Current report Filed: 2018-05-02 AccNo: 0001564590-18-010068 Size: 985 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接